Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01809028 · ClinicalTrials.gov registry record · NA
Evaluating the Number of Passes Required for Diagnostic Cell Block During EUS-FNA of Solid Pancreatic Mass Lesions
A NA study, sponsored by AdventHealth.
- Completed
- Registry status
- NA
- Development phase
- 62
- Enrollment target
NCT01809028 is a NA study that has completed, run by AdventHealth. The registered enrollment target is 62 participants.
The verdict
NCT01809028, a NA study, has completed, sponsored by AdventHealth.
- COMPLETED
- Registry status
- NA
- Development phase
- 62 participants
- Enrollment target
Study Summary
This study will test the amount of tissue, called "cell block", obtained from your pancreas. Patients who are asked to participate in this study have a growth (mass) in the pancreas that needs a biopsy so a diagnosis can be made. Although we usually perform 2 to 4 passes (number of times the doctor biopsies the mass), at this time we do not know the ideal number of passes needed to obtain adequate amount of tissue for making a diagnosis. The purpose of this study is to compare the amount of tissue obtained with 2 passes versus 4 passes.
Interventions
- PROCEDURE EUS FNA with 2 passes
- PROCEDURE EUS FNA with 4 passes
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2013-02 |
| Est. Completion | 2014-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01809028
The ClinicalTrials.gov registry entry for NCT01809028 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AdventHealth, which has 95 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which EUS FNA with 2 passes is the first listed.
NCT01809028 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01809028 about?
NCT01809028 is a clinical study titled "Evaluating the Number of Passes Required for Diagnostic Cell Block During EUS-FNA of Solid Pancreatic Mass Lesions". This study will test the amount of tissue, called "cell block", obtained from your pancreas. Patients who are asked to participate in this study have a growth (mass) in the pancreas that needs a biopsy so a diagnosis can be made. Although we usually perform 2 to 4 passes (number of times the doctor ...
What is the current status of trial NCT01809028?
This trial is currently completed. It is a NA study. The enrollment target is 62 participants. The study started on 2013-02. Estimated completion is 2014-01.
What interventions are being tested in trial NCT01809028?
The interventions under investigation include: EUS FNA with 2 passes (PROCEDURE), EUS FNA with 4 passes (PROCEDURE).
Who is sponsoring clinical trial NCT01809028?
This trial is sponsored by AdventHealth, which has 95 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.